Ontology highlight
ABSTRACT:
SUBMITTER: Zambrowicz B
PROVIDER: S-EPMC3400893 | biostudies-literature | 2012 Aug
REPOSITORIES: biostudies-literature
Zambrowicz B B Freiman J J Brown P M PM Frazier K S KS Turnage A A Bronner J J Ruff D D Shadoan M M Banks P P Mseeh F F Rawlins D B DB Goodwin N C NC Mabon R R Harrison B A BA Wilson A A Sands A A Powell D R DR
Clinical pharmacology and therapeutics 20120704 2
Thirty-six patients with type 2 diabetes mellitus (T2DM) were randomized 1:1:1 to receive a once-daily oral dose of placebo or 150 or 300 mg of the dual SGLT1/SGLT2 inhibitor LX4211 for 28 days. Relative to placebo, LX4211 enhanced urinary glucose excretion by inhibiting SGLT2-mediated renal glucose reabsorption; markedly and significantly improved multiple measures of glycemic control, including fasting plasma glucose, oral glucose tolerance, and HbA(1c); and significantly lowered serum triglyc ...[more]